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Fibrolamellar hepatoma (FL-HCC) is an uncommon variant 
of hepatocellular carcinoma (HCC), distinguished by histo-
pathological features suggesting greater differentiation than 
conventional HCC. However, the optimal treatment and the 
prognosis of FL-HCC have been controversial. Follow-up 
studies are available from 1 year to 27 years, after 41 patients 
with FL-HCC were treated with partial hepatectomy (PHx) 
(28 patients) or liver transplantation (13 patients). In this 
retrospective study, the effect on outcome was determined 
for the p TNM stage and other prognostic factors routinely 
recorded at the time of surgery. Cumulative survival at 1,3, 
S, and 10 years was 97.6%, 72.3%,66.2%, and 47.4%. Tumor-
free survival at these times was 80.3%, 49.4%, 33%, and 
29.3%. The TNM stage was significantly associated with tu-
mor-free survival. Patients with positive nodes had a shorter 
tumor-free survival than those with negative nodes (P < .015). 
Patient survival was most adversely affected by the presence 
of vascular invasion (P < .05). FL-HCC is an indolently grow-
ing tumor of the liver, which usually was diagnosed in our 
patients at a stage too advanced for effective surgical treatment 
of most conventional HCC. Nevertheless, long-term survival 
frequently was achieved with aggressive surgical treatment. 
When a subtotal hepatectomy could not be performed, total 
hepatectomy (THx) with liver transplantation was a valuable 
option. (HEPATOLOGY 1997;26:877-883.) 
Fibrolamellar hepatoma (FL-HCC) was first described by 
Edmondsonl as a rare histological variant of hepatocellular 
carcinoma (HCC). Although several reports have emphasized 
the indolent growth of this subtype as well as a higher sur-
vival than with surgical treatment of conventional HCC, the 
better postoperative prognosis has been questioned or de-
nied. 2,3 
Resolution of this controversy has been hampered by the 
paucity of long-term follow-up data after surgical therapy for 
FL-HCC. Exclusive of the 41 patients described herein (some 
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previously reported4-b), less than 100 such cases can be found 
in the literature.2.3·7-l7 In our series, we have compared the 
survival of patients with FL-HCC with that of patients with 
conventional HCC who were treated by the same team over 
a 27 -year period. 
PATIENTS AND METHODS 
Case Material 
Between 1968 and 1995,477 patients with hepatoma underwent 
hepatiC resection or orthotopic liver transplantation (OlT). Forty-
one (8.9%) of the 477 patients had FL-HCC. Four were treated at 
the University of Colorado (before 1980), and the remaining 37 at 
the University of Pittsburgh Medical Center. There were 23 males 
and 18 females. The 41 patients were 29.5 ::!::: 13.7 (SO) years old 
(range, 9-66; median, 25) (Fig. 1). The median follow-up was 58 
::!::: 9.3 months. 
Clinicopathological Characteristics 
The pathology reports and operative findings were used to deter-
mine: the principal tumor size, number of lesions, lobar distribu-
tion, vascular and lymphatic tumor extension, surgical margins, 
distant metastases, and the presence or absence of associated cirrho-
sis. When available, the tumor markers were recorded as well as 
the virus markers (hepatitis C virus, hepatitis B virus). 
Staging was with the pTNM classification proposed by the Inter-
national Union Against Cancer and the American Joint Committee 
on Cancer. 18.19 Thirty-seven of the 41 patients had stage IV tumors 
at the time of surgery (Table 1). 
Surgical Procedures 
Partial hepatectomy (PH x) was the procedure of choice. Total 
hepatectomy (THx) and OLT were performed when tumor exten-
sion or the presence of underlying liver disease precluded PHx. Both 
PHx and THx were frequently performed under highly unfavorable 
conditions, such as lymph node involvement and/or direct invasion 
of tumor into the adjacent organs· 
Sublolal Hepatectomy (PHx). In 8 of the 28 patients. resection in-
cluded one or more surrounding organs in an attempt 10 secure 
tumor-free margins. The types of PHx performed in this group are 
summarized in Table 2, using surgical techniques that have been 
described elsewhere 2o.11 
THx and OLT. In 6 of these 13 patients, the THx was extended 
to adjacent organs (Table 2). Two patients had upper abdommal 
exenteration and organ cluster transplantatlon. 2UJ In 1 patient, 
Ol T was combined with pancreaticoduodenectomy (Whipple pro-
cedure). The surgIcal techmques for Oll and the immunosuppres-
sion used thereafter have been described elsewhere. 22.1h Immuno-
suppression was with cyclosporine and prednisone (n = 9), imuran 
and prednisone In == I), or tacrolimus and prednisone (n = 3). 
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FIG. 1. HCC-FL: age and gender distribution by decades of age. 
(D) All patients; C.) male patients; and CD) female patients. 
Adjuvant Therapy 
Sixteen patients received adjuvant radiotherapy or chemotherapy 
before and/or after surgery (Table 3). These regimens were highly 
variable in the long period of the study. Adriamycin ::!: Cis-Platinum 
were most commonly used. 
Statistical Analysis 
Cumulative overall survivals and tumor-free survivals were calcu-
lated by the method of Kaplan-Meier with adjustment for types of 
surgery (OLT vs. PHX).27 Potential risk factors studied by univariate 
analvsis were tumor size, number of lesions, lobar involvement, 
vasc~lar invasion, lymph node invasion. distant metastases, pTNM 
stage, surgical margins, and adjuvant chemotherapy. P < .05 was 
considered significant. The small number of patients with different 
potential risk factors precluded multivariate analysis. 
RESULTS 
Pathological Characteristics 
Tumor Size. Number, and Lobar Distribution. The principal 
tumors had a median diameter of 13 cm (mean::!: SD = 12.4 
::!: 4.3 em) with a range between 3 to 25 cm. Thirty patients 
(73°1.1) had a single tumor. The remaining 11 patients (27%) 
had two or more lesions. The tumor(s) was bilobar in 30 
patients (73%). The tumor(s) involved only the left lobe in 
7 patients and the right lobe in 4 (Tables + and 5). 
Vascular Invasion. Ten patients (24.4%) had no evidence of 
vascular invasion (VO), 21 (51.2%) had microvascular inva-
sion (Vl). and 10 (24.4%) had gross vascular invasion (V2) 
(Tables 4 and 5). The main branch of the portal vein or the 
portal vem trunk was involved in 7 of the 10 cases with V2. 
There was one example of inferior vena cava invasion. and 
two of the hepatic vein. 
.\Iargills. The margins of resection were free of tumor (RO) 
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TABLE 2. Surgical Treatment of FL-HCC 
Hepatic ReseclIon (n = 28) 
Right trisegmentectomy (n = 12) 
Adrenal + diaphragm resection 
Diaphragm resection 
Left trisegmentectomy (n = 7) 
Stomach + omentum + diaphragm rcseCllon 
Diaphragm resection 
Left hepatectomy (n = -+) 
Right hepatectomy (n = 1) 
Left lateral segmentectomy (n = 2) 
Celiac axis LN resection 
Wedge resection (n = 2) 
Omentum + periaortic LN resection 
Liver transplantation (n = 13) 
Standard OLT (n = 7) 
OLT + pylorus + omentum resect. (n = 1) 
OLT + diaphragm resect. (n = 1) 
OLT + adrenal + diaphragm resection (n = 1) 
OLT + Whipple procedure (n = 1) 
OLT + cluster resection (n = 2) 
NOTE. n = 41. 
:'-/0. of Patients 
2 
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in 34 cases. The margins of resection were microscopically 
positive (Rl) in 4 other patients and grossly positive (R2) in 
the remaining 3 (Tables 4 and 5). 
Metastases. Thirteen patients (31.7%) had regional meta-
static disease (Ml) at the time of surgery (Tables 4 and 5), 
which was resected in continuity with the principal tumor 
(Table 6). 
Cirrhosis, Tumor Markers, and Serology. Three patients in the 
OLT group had associated cirrhosis (7.3%). One of these 
patients is alive 120 months after OLT, 1 died with tumor 
recurrence at 25 months, and the third patient died at 66 
months with tumor recurrence. 
Nineteen patients were tested for a-fetoprotein, with only 
2 00.5%) elevations. However, all of the 10 patients tested 
for Des-y-carboxy prothrombin 2H had elevated serum levels 
despite normal levels of a-fetoprotem. 
Of the 30 patients tested for hepalltis B virus, none had a 
positive serology. The positive rate for hepatitis C virus was 
1 of 17 tested. 
TNM Stage. The pTNM stages of the 41 patients are sum-
marized in Tables 1 and 4; 90.2% presented with pTMN 
stage IVA or [VB. One of the 2 patients with stage [I was 
transplanted for decompensated cirrhosis; the FL-HCC was 
an incidental finding in the surgical specimens. 
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T\BLE 4. Tumor-Free Survival 
PHxlOLT PHxlOLT 
Risk Factor (n) p (mean - SE [moil 
Tumor size 
$10 em 10/2 >.2 112.1 ::: 30.4/83.0 = 26.2 
>10 em 18111 73.9 ::: 20.21-+4-+ ::: 15.0 
Tumor 
SlIlglc 2119 7 lJh9 :':: 22.0/58.5 = 19.3 
MulLip[e 714 59.7 :':: 22.6/34.8 :':: 10.6 
Oistribullon 
Unilobar 8/3 >.8 47.9 :!: 14.7/59.7 ::: 25.8 
Bilobar 20110 100.9 :!: 22.91-+7.9 ::: Ih.3 
:-Vlargins 
(- ) 23111 >.9 63.8 :!: 27.6/62.8 :!: 19.7 
(+) 5/2 100.7 :!: 22.7/30.3 :!: 15.5 
Lymph nodes 
(- ) 19/8 <.015 119.1 :!: 23.5/14.6 :!: 24.1 
(+ ) 915 23.4 :!: 6.0129.6 :':: 9.2 
Vascular invaSIOn 
VO 911 >.16 109.9:!: 29.51120.0 :!: 00 
VI 1813 79.9 :!: 21.8/33.0 :!: 11.7 
\2 119 5.0 :!: 0.01-+6.4 ::: 16.9 
Metastasts 
MO 18110 <.003 135.2 :!: 24.3/63.4 :!: 19.5 
Ml 10/3 21.4:!: 6.7/28.0 :':: 12.1 
pTNM stage 
I, I!, 1lI, and [VA IBl10 <.003 135.2 :!: 24.3/63.4 :!: 19.5 
IVB 10/3 21.4 :!: 4.4/28.0 :!: 4.9 
Chemo/radiation 
No 2017 <.013 100.5 ::: 19.5184.9 :!: 25.9 
Yes Bl6 43.9 :!: 25.1/26.8 :!: 8.0 
Survival Rate 
There were no deaths within 6 months after either PHx 
or OL T. Thereafter, survival after PHx was consistently supe-
rior, and, at ') years, the gap was 44% (Fig. 2). However, 
because the conditions dictating the use of THx and OL T 
were different than those for PHx, comparison of survival 
with these therapeutiC modalities has little value. Of the 18 
patiellls who died after the surgical treatment. 16 died from 
causes related to the tumor occurrences. Two patients, both 
in the OL T group. died from sepsis 
The cumulative survival and the tumor-free survival of the 
combined cohorts are shown in Fig. 3. The mean cumulative 
survival was 126.93 ::J::: 16.34 (SE) months. The mean tumor-
tree survival was 86.93 ::J::: 15.24 (SE) months. The cumulative 
survivals and the tumor-free survivals, stratified according 
to the plNM stages. are shown 111 Table 7. The differences 
III the cUlllulatL\'e survivals and tumor-free survivals among 
the pT0;M stages were statistically Significant (Table 7). 
rhe lI1i1uence 01 nine clinicopathological Llctors ,1I1 tumor-
free and m'l'rall Sllr\"l\'als were examined bv uni\'ariate anah-
.,IS (Llbles -+ 'lI1d 5). The invohl'mel1l ,If regional 1\l11ph 
nodes \" Il. the presence olml'tastasls I ~111K and advancl'd 
p TNt-.l stage wcre stallsll<.:alh· slgntlic;\I1t prognost IC iactors 
reducing tUll1or-lree slln·Lvals. ,\Ithough thl'sC Ltctors did not 
II1dindllalh Illllucnce the o\'l'r'lll "urnval at a '>t;tllsllcalh' 
slgmlic'Il1L kn'l. sllr\"l\'al of thl' P'tlll'IlLS \\'Ilh st,lge l\'n ""IS 
slgntilGII1lh' I'l\\l'r (han (haL III thl''>l' \\Ith ,>l.lgC,> II ,lIld III 
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TABLE 5. Patient Survival 
Risk Factor 
Tumor size 
::0;10 em 
>10 em 
Tumor 
Single 
Multiple 
Distribution 
Unilobar 
Bilobar 
Margins 
(- ) 
(+ ) 
Lymph nodes 
(-) 
(+) 
Vascular invasion 
VO 
VI 
V2 
Metastasis 
MO 
Ml 
pTNM stage 
I, 11, 1lI, and IVA 
IVB 
Chemo/radiation 
No 
Yes 
PHxlOlT 
in) 
10/2 
I BIll 
21/9 
71-+ 
8/3 
20/10 
23/11 
5/2 
19/8 
9/5 
9/1 
1813 
1/9 
18/10 
10/3 
18/10 
10/3 
2017 
8/6 
p 
>.06 
>.6 
>.65 
>.48 
>.18 
<.05 
>.18 
>.18 
>.09 
PHxlOLT 
(mean::: SE ImoD 
190.7 :':: 23.4/93.0 :!: ILJ.I 
1163 :!: 22.7/53.1 :!: 144 
166.1 :!: 22.4/61.7 :!: 18.0 
106.5 :!: 23.0/45.0 ::: 8.0 
121.3 :!: 23.2170.3 :':: 22.5 
155.5 :!: 23.0/55.9 :!: 8.3 
146.8 :!: 29.7/68.6 :!: 17.8 
153.3 :!: 23.2141.0 :!: 12.7 
173.0 :!: 20.0/61.8 :!: 18.8 
55.0 :!: 11.7/55.6 :!: 18.5 
81.9 :!: 20.Bl120.0 :!: 0.0 
\30.2 :!: 23.5/34.0 :!: 7.8 
26.0 :!: 0.0156.1 :!: 15.8 
177.7 :!: 21.1/60.3 :!: 16.1 
69.1 ::: 14.5144.0 :!: 16.2 
177.7 :!: 21.1160.3 :!: 16.1 
69.1 :!: 14.5/44.0 :!: 16.2 
156.7:!: 17.6/67.0 :!: 20.7 
102.3 :!: 36.1150.5 :!: 15.8 
lar invasion of the tumor was a statistically Significant 
prognostic factor reducing overall survival, but it did not 
influence tumor-free survivaL Unexpectedly, adjuvant che-
motherapy tended to decrease the tumor-free survival (Tables 
4 and 5). 
Tumor Recurrence and Treatment 
Recurrence of FL-HCC was confirmed in 27 (65.8%) 01 
the 41 patients during the stud" period: 18 (6-+.2%) of the 
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FIG. 2. Fl-HCC: patient survival after PHx and THx with alI. 
28 treated with PHx and 9 (69.2%) of the 13 treated with 
THx and OLT. The time and site of tumor recurrence, treat-
ment used for recurrence, and survival after diagnosis are 
summarized in Table 8. The liver was the organ most often 
involved, followed by the lungs and intra-abdominal lymph 
nodes. 
Attempts at re-resection were made in 6 patients whose 
original surgery was PHx, and 3 who already had undergone 
THx and OLT. The secondary surgeries ranged from minor 
procedures to the drastic step of complete liver replacement 
in 3 cases, followed by survival of 2, 12, and 30 months 
(Table 8). After the diagnosis of tumor recurrence, the 18 
patients initially treated with PHx lived for 1 to 80 months; 
the 9 first treated with OLT lived for 0 to 43 months. The 
overall actuarial postrecurrence survival in the combined 
group (n = 27) at 1,3, and 5 years was 75%, 48%, and 28%, 
respectively (Fig. 4). The survival of the 9 patients whose 
recurrence was treated by surgical resection with or without 
combined chemotherapy was slightly better than that of the 
13 patients who were treated with chemotherapy alone, but 
the difference was not statistically Significant. 
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Five-Year Survivors 
Of the 31 patients treated more than 5 years ago. 19 
(61.3%) achieved actual survival of at least 5 years; 15 (75%) 
of the 20 patients in the hepatiC resection group and 4 
(36.3%) of the 11 treated with OLT (Table 9 and Fig. 2). All 
4 patients with tumor stage II or III survived for more than 
5 years compared with 12 (63.1%) of the 19 with tumor 
stage IVA, and only 3 (37.5%) of 8 with tumor stage IVB. 
One of the 3 long survivors in the IVB group died after 7 
years; the other 2 are alive with tumor after 7 and 9 years 
(PHx 10 and 14) (Table 9). The time of survival postrecur-
renee in these unusual cases has been 6.67 and 4.33 years. 
DISCUSSION 
FL-HCC was first identified by its unique histological fea-
tures l and distinctive clinical behavior. I.7 In our study (see 
Fig. 1), as well as in collected cases from the literature, FL-
HCC showed a unimodal age distribution with the peak in 
the third decade. In contrast. common HCC has a bimodal 
age distribution when it occurs in the noncirrhotic liver with 
the peaks in the third and in the sixth decade,29.3o and a 
unimodal peak in the fifth or sixth decade when cirrhosis is 
present. 30 The conventional HCC is more frequent in males 
than females, but the FL-HCC is found almost equally in 
females (44% in our series). FL-HCC is rarely found in the 
cirrhotic liver,3.5.9 as was exemplified by only 3 (7.3%) of the 
41 cases reported herein. 
The tumor markers of FL-HCC have a characteristic pat-
tern. In our series, only 10.5% of the patients tested had 
elevated serum a-fetoprotein levels, while the Des-'}'-carboxy 
prothrombin serum level was elevated in all who were tested. 
The Des-'}'-carboxy prothrombin level also identified tumor 
recurrence, whereas the AFP did not. High levels of neuro-
tens in and vitamin B12 binding capacity also have been re-
ported with FL_HCC,II.13.31 but these were not determined 
in our cases. 
The indolent growth of FL-HCC and an excellent long-
term survival after surgery was first emphaSized by Craig et 
al. 7 and by Berman et al.H in 1980. based largely on cases 
collected from the literature. Although Nagorney et al. were 
the first to question the prognostic SIgnificance of this diag-
nosis in 1985,2 our report 1 year later+ contained evidence 
that patients with FL-HCC were excellent candidates for ag-
gressive surgery. Since then, the clinical Significance of a 
histopathological diagnosis of FL-HCC has been debated 
among investigators. analyzing small numbers of their own 
cases in combination with reviews of the literature. Some 
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TABLE 8. Time and Site of Recurrence. Treatment of Recurrence. and Survival After the Diagnosis of Recurrence 
Time of Recurrence Treatment of Survival After Recurrence 
Patient (mo) Site of Recurrence Recurrence (mo) Status 
Hx 6 110 \1edistinum LN + chest wall CT + RT -+0 ,\WT 
Hx 7 41 Liver OLI 30 OWT 
Hx 9 30 Lung CT 10 OWT 
Hx 10 30 Peritoneum + liver CT 80 ,\WT 
Hx 11 0 Abdominal LN + liver CT 17 OWT 
Hx 13 18 Stomach + pentoneum + liver CT 9 OWT 
Hx 1+ 30 Liver 52 AWT 
Hx 15 8 Lung + abdominal LN CT 7 OWT 
Hx 16 5 .\bdominal LN + bone + lung CT 68 OWT 
Hx 18 23 Lung Sx. 1+ AWT 
Hx 19 33 Lung CT + Sx. 4 AWT 
Hx 20 5 Paraortlc LN + liver CT + Sx. 21 AWT 
Hx 22 13 Paraortic LN + liver CT 6 AWT 
Hx 23 64 Liver 5x. 2 AFT 
Hx 24 10 Retroperit. LN 4 AWT 
Hx 25 5 Paraaortic LN + adrenal Rt. CT 7 AWT 
Hx 26 7 Liver CT AWT 
Hx 28 -12 Chest wall + mediast. + CI + 5x. 46 OWl 
paraaortic LN + liver + IVC 
OLll 12 Liver + diaphragm + chest OLI 2 OWT 
wall + lung + retroperi!. LN 
OLI 2 32 Pelvis + diaphragm 0 OWT 
OLI 5 16 Lung CT 16 OWT 
OLI 8 13 Liver OLI 12 OWT 
OLI 9 52 Liver + pancreas + adrenal Rt 43 OWT 
OLI 10 13 SMA LN CT 3 OWT 
OLI 11 19 Medias!. LN + bone + lung CT + RT 39 OWT 
OLI 12 46 Lung 20 OWT 
OLT 13 52 Lung 5x. 6 AWT 
Abbreviations: CT, chemotherapy: RT. radiotherapy; 5x. surgery: SMA. superior mesenteric artery: LN. lymphnode: AfT. alive free of tumor: OWT, 
death with tumor: A WT. alive with tumor. 
authors have not found the diagnosis of FL-HCC to confer 
a survival advantage. Jl4 but others confirmed the original 
claims,IUl.l7 
The -+ I pallents with FL-HCC reponed herein of whom 
31 were operated upon more than 5 years ago constitute the 
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largest series with the longest follow-up known to exist. The 
cases were accrued over a 3-decade period by a Single group 
of surgeons committed to aggressive treatment of these neo-
plasms. Despite the fact that 900;':) of tumors presented with 
p TNM stage IVA or [\'13. our overall actuanal sllrvlval was 
TABLE g, List of 19 five-Year Survivors 
Case No. Age/Sex pta~e Recurrcllfc Survival 
Hx I 9fM IVA "io Alive ILJ \T 
Hx 2 311F IVA '\0 Alive 17 \T 
Hx 3 t)fM IVA :'\0 .\\tvc Ih \T 
Hx -I HfM IVA :\,) .\Iive I l \T 
Hx 5 l3,0.1 IVA ~n Alive 1.3 \T 
lix h ·HlfM IVA ll'S .\II\T I l I r 
IIx 7 231M IVA viD~ Died 6 I I 
Ih8 1l)/M II ,\" .\Iive WII 
fix tl1 5tJ/f IYB 'I l'S .\\tve t) I' 
Hx 12 231M I\A '\ ,I .\llvc 1'1 I r 
fix 14 2(l/f 1\£1 'I C ... Kyllq~ I I' 
IIx It) \lJ/f 1\'.\ ll·..., Died h I I 
IIx 23 -+51f III '\(l \11\'1' () I r 
fix 27 \ l)1f III 1l'''' Died l2 \! 
Ih 28 llF/~1 1\ B It· .... Di,'t! I I' 
l)L T 3 2h/M 1\.\ 'w \1,vl' I l I, 
l lL T I -+V\I II ,\, t .\lln· Il! \I 
llL T q 2-1/\\ 1\.\ \ t· ... Dietl 1'1 \ r 
l )I.T 12 )1'1/\1 1\ .1 I ,- I )Ini () \ r 
I ,. 
II 
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66.2% at 5 years and 47.4% at 10 years. The higher survival 
compared with that reponed by olherse.3 could be explained 
in part by our wide use of extensive hepatic resection (includ-
ing adjacent structures) at the original surgery, and an aggres-
sive surgical approach to the recurrent tumors. 
However, the most important factor obViously was the 
biological behavior of FL-HCC, the results with which can 
be compared with our contemporaneous experience with 
conventional HCC. In patients with HCC in noncirrhotic 
liver. 5-year global survival was 43.7% after hepatic resection 
and 26% after transplantation." However, the 5-year survival 
when the HCC was stage IVA was only 16.8% after PHx and 
10.9% afler OLT,b similar to the experience of others.J2.3A 
The indolent growth of FL-HCC was especially obvious 
when recurrences developed. Even after the diagnOSis of tu-
mor recurrence, survival was 75% at 1 year, 48% at 3 years, 
and 28% at 5 years (Fig. 4). Surgical excision of recurrent 
tumor with or without chemotherapy may have prolonged 
survival, but, if so, only minimally. Cytoreductive chemo-
therapy was clearly ineffective. Adjuvant chemotherapy from 
the outset did not improve survival. However, the impression 
that it may have been harmful (see Tables 4 and 5) reflected 
in part the selection for chemotherapy of patients with ad-
vanced tumor stage. Of the 16 patients who received adjuvant 
chemotherapy, 6 had stage IVA and 10 had stage IVB tumor. 
Eleven patients had positive lymph nodes, and 15 patients 
had vascular invasion by the tumor. 
Because of the limited number of cases at stages II and III, 
a conventional analysis of stratification-specific prognostic 
factors could not be performed. However, the good results 
obtained with hepatic resection or transplantation for FL-
HCC that was staged at IVA or IVB in >90% of cases can 
be construed as evidence of the indolent growth, favorable 
natural behavior, and SUitability for aggressive treatment of 
these tumors. 
In conclusion, the therapeutic approach that we recom-
mend for FL-HCC is wide hepatic resection including the 
adjacent structures if they are invaded by the tumor. PHx is 
the treatment of choice if at least one liver segment can be 
saved. If the presence of underlving liver disease or the loca-
tion of the tumor preclude PHx, THx with OlT should be 
consIdered. ,\djuvant chemotherapy so far has not shown 
anv hendit in patient survival and tumor-free interval. An 
aggressive surgical approach of tumor recurrences after pri-
mary treatment can extend the patient survival. 
:ydll1Egwlccl~fllClfl: The authors thank Dr. Mohamed A. 
\'irji tor hIS assistance in compiling the data on blood tumor 
markers. and advice on their tnterpretation. 
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